AUSTIN, Texas, Jan. 6 /PRNewswire/ -- DiFUSION Technologies, Inc., a medical device company targeting the orthopaedic market, today announced its corporate launch. The company will focus on reducing the rising incidence of Surgical Site Infections (SSIs) in spinal surgeries.
"In large studies, five out of 100 spine cases result in SSIs often leading to second surgeries that are extremely costly and difficult for the patient," said Dr. Matthew Geck, founder and board member of DiFUSION and leading orthopaedic surgeon in Austin, Texas. "DiFUSION will release a medical device in 2009 capable of killing 650 types of bacteria including antibiotic-resistant bacteria such as MRSA (also known as "Superbugs") in the local surgical wound for up to four weeks following surgery."
DiFUSION's founding and scientific board members comprise a team of recognized physicians in the field of spinal, biochemical and genetic research, and senior executives hold extensive experience in spinal product development and clinical studies.
"DiFUSION's solution may not only improve infection ratios, the 'super silicate' technology will also affect the bone remodeling sequence in a potentially positive fashion," said Dr. Peter Whang, a member of DiFUSION's scientific advisory board and an Assistant Professor in the Department of Orthopaedics and Rehabilitation at the
"The controlled delivery of cationic elements possible with our 'super silicate' open multiple promising applications from infection control to bone growth," said Dr. Gary Ghiselli, chair of the DiFUSION scientific advisory board and a board-certified orthopaedic surgeon in Denver, Colorado, who exclusively focuses
|SOURCE DiFUSION Technologies, Inc.|
Copyright©2009 PR Newswire.
All rights reserved